iTeos Therapeutics (NASDAQ:ITOS – Get Rating) had its price objective lowered by analysts at JPMorgan Chase & Co. from $34.00 to $32.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price would suggest a potential upside of 126.63% from the stock’s previous close.
Separately, Wedbush lowered their price objective on iTeos Therapeutics from $45.00 to $33.00 and set an “outperform” rating for the company in a research note on Thursday.
iTeos Therapeutics Stock Down 4.4 %
Shares of NASDAQ ITOS opened at $14.12 on Thursday. iTeos Therapeutics has a fifty-two week low of $13.81 and a fifty-two week high of $37.26. The business has a 50 day moving average price of $18.81 and a two-hundred day moving average price of $19.42. The firm has a market cap of $502.39 million, a PE ratio of 2.05 and a beta of 1.42.
Institutional Inflows and Outflows
iTeos Therapeutics Company Profile
Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.
- Get a free copy of the StockNews.com research report on iTeos Therapeutics (ITOS)
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.